409 related articles for article (PubMed ID: 26462862)
1. Vitamin D and axonal injury in multiple sclerosis.
Sandberg L; Biström M; Salzer J; Vågberg M; Svenningsson A; Sundström P
Mult Scler; 2016 Jul; 22(8):1027-31. PubMed ID: 26462862
[TBL] [Abstract][Full Text] [Related]
2. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease.
Peng L; Bi C; Xia D; Mao L; Qian H
Mult Scler Relat Disord; 2019 May; 30():123-128. PubMed ID: 30771578
[TBL] [Abstract][Full Text] [Related]
3. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
4. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
Novakova L; Zetterberg H; Sundström P; Axelsson M; Khademi M; Gunnarsson M; Malmeström C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J
Neurology; 2017 Nov; 89(22):2230-2237. PubMed ID: 29079686
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.
Villar LM; Picón C; Costa-Frossard L; Alenda R; García-Caldentey J; Espiño M; Muriel A; Álvarez-Cermeño JC
Eur J Neurol; 2015 Aug; 22(8):1169-75. PubMed ID: 25324032
[TBL] [Abstract][Full Text] [Related]
6. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.
Fialová L; Bartos A; Svarcová J; Zimova D; Kotoucova J; Malbohan I
J Neuroimmunol; 2013 Sep; 262(1-2):113-20. PubMed ID: 23870535
[TBL] [Abstract][Full Text] [Related]
7. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.
Lycke JN; Karlsson JE; Andersen O; Rosengren LE
J Neurol Neurosurg Psychiatry; 1998 Mar; 64(3):402-4. PubMed ID: 9527161
[TBL] [Abstract][Full Text] [Related]
8. High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
van der Vuurst de Vries RM; Wong YYM; Mescheriakova JY; van Pelt ED; Runia TF; Jafari N; Siepman TA; Melief MJ; Wierenga-Wolf AF; van Luijn MM; Samijn JP; Neuteboom RF; Hintzen RQ
Mult Scler; 2019 Jun; 25(7):958-967. PubMed ID: 29774770
[TBL] [Abstract][Full Text] [Related]
9. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
[TBL] [Abstract][Full Text] [Related]
10. Neurofilament light chain in the assessment of patients with multiple sclerosis.
Domingues RB; Fernandes GBP; Leite FBVM; Senne C
Arq Neuropsiquiatr; 2019 Jul; 77(6):436-441. PubMed ID: 31314847
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of CSF neurofilament light and heavy chain protein in MS.
Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis.
Gaetani L; Salvadori N; Lisetti V; Eusebi P; Mancini A; Gentili L; Borrelli A; Portaccio E; Sarchielli P; Blennow K; Zetterberg H; Parnetti L; Calabresi P; Di Filippo M
J Neurol; 2019 Sep; 266(9):2157-2163. PubMed ID: 31129709
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D
Smolders J; Mimpen M; Oechtering J; Damoiseaux J; van den Ouweland J; Hupperts R; Kuhle J
Acta Neurol Scand; 2020 Jan; 141(1):77-80. PubMed ID: 31657006
[TBL] [Abstract][Full Text] [Related]
14. Neurofilaments and 10-year follow-up in multiple sclerosis.
Bhan A; Jacobsen C; Myhr KM; Dalen I; Lode K; Farbu E
Mult Scler; 2018 Sep; 24(10):1301-1307. PubMed ID: 30066611
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis.
McComb M; Krikheli M; Uher T; Browne RW; Srpova B; Oechtering J; Maceski AM; Tyblova M; Jakimovski D; Ramasamy DP; Bergsland N; Krasensky J; Noskova L; Fialova L; Weinstock-Guttman B; Havrdova EK; Vaneckova M; Zivadinov R; Horakova D; Kuhle J; Ramanathan M
J Clin Lipidol; 2020; 14(5):675-684.e2. PubMed ID: 32758395
[TBL] [Abstract][Full Text] [Related]
16. CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
Romme Christensen J; Komori M; von Essen MR; Ratzer R; Börnsen L; Bielekova B; Sellebjerg F
Mult Scler; 2019 Jun; 25(7):937-946. PubMed ID: 29775134
[TBL] [Abstract][Full Text] [Related]
17. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
[TBL] [Abstract][Full Text] [Related]
18. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Fitzgerald KC; Munger KL; Köchert K; Arnason BG; Comi G; Cook S; Goodin DS; Filippi M; Hartung HP; Jeffery DR; O'Connor P; Suarez G; Sandbrink R; Kappos L; Pohl C; Ascherio A
JAMA Neurol; 2015 Dec; 72(12):1458-65. PubMed ID: 26458124
[TBL] [Abstract][Full Text] [Related]
19. Assessing tissue damage in multiple sclerosis: a biomarker approach.
Burman J; Zetterberg H; Fransson M; Loskog AS; Raininko R; Fagius J
Acta Neurol Scand; 2014 Aug; 130(2):81-9. PubMed ID: 24571714
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes.
Martinelli V; Dalla Costa G; Colombo B; Dalla Libera D; Rubinacci A; Filippi M; Furlan R; Comi G
Mult Scler; 2014 Feb; 20(2):147-55. PubMed ID: 23836877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
